Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab

American Journal of Gastroenterology

Volumn 107, Issue 8, 2012, Pages 1266-1268

  Uraoka, Yoshika ^a   Tanigawa, Tetsuya ^a   Watanabe, Kimihiko ^a   MacHida, Hirohisa ^a   Okazaki, Hirotoshi ^a   Yamagami, Hirokazu ^a   Watanabe, Kenji ^a   Tominaga, Kazunari ^a   Watanabe, Toshio ^a   Fujiwara, Yasuhiro ^a   Arakawa, Tetsuo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN TC 99M; ALPHA 1 ANTITRYPSIN; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; HEPARIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; RO ANTIBODY; TRANEXAMIC ACID;

ADULT; B LYMPHOCYTE; CASE REPORT; CLINICAL FEATURE; DRUG PULSE THERAPY; DRUG TREATMENT FAILURE; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOALBUMINEMIA; IMMUNOREACTIVITY; LETTER; LYMPHOCYTIC INFILTRATION; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN LOSING GASTROENTEROPATHY; REMISSION; SJOEGREN SYNDROME; TARGET CELL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; PROTEIN-LOSING ENTEROPATHIES; REMISSION INDUCTION; SJOGREN'S SYNDROME;

EID: 84864612083     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.92     Document Type: Letter

References (12)

1. Miyawaki S. Revised Japan criteria for Sjogren syndrome. Ryumachi 2000; 40: 48-53. (Pubitemid 30246333)
2. Vitali C, Bombardieri S, Jonsson R et al. Classifi-cation criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8. (Pubitemid 34539104)
3. Ramos-Casals M, Soto MJ, Cuadrado MJ et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009; 18: 767-76.
4. Bomback AS, Derebail VK, McGregor JG et al. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009; 4: 734-44.
5. Alcantara C, Gomes MJ, Ferreira C. Rituximab therapy in primary Sjogren's syndrome. Ann N Y Acad Sci 2009; 1173: 701-5.
6. Tsutsumi A, Sugiyama T, Matsumura R et al. Protein losing enteropathy associated with collagen diseases. Ann Rheum Dis 1991; 50: 178-81.
7. Nakajima A, Ohnishi S, Mimura T et al. Protein-losing enteropathy associated with hypocomplementemia and anti-nuclear antibodies . J Gastroenterol 2000; 35: 627-30. (Pubitemid 30649500)
8. Itoi K, Sasaki T, Sawai T et al. Protein-losing gastroenteropathy in association with immune deposits in gastrointestinal mucosal capillaries. Am J Gastroenterol 1989; 84: 187-91. (Pubitemid 19060757)
9. Edwards JC, Szczepanski L, Szechinski J et al. Effi cacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81. (Pubitemid 38758544)
10. Meijer JM, Meiners PM, Vissink A et al. Eff ectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2010; 62: 960-8.
11. Keogh KA, Wylam ME, Stone JH et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262-8. (Pubitemid 40129256)
12. Cross JT, Benton HP. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Infl amm Res 1999; 48: 255-61. (Pubitemid 29257616)